{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:10:05Z","timestamp":1795108205328,"version":"4.10.3"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interstitial lung disease (ILD) is the most common complication and the major cause of mortality among patients with idiopathic inflammatory myopathies (IIMs). Currently, no recommended standard treatment for IIM-associated ILD. In this observational study, we evaluated the efficacy and safety of telitacicept in treating IIM-associated ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included 10 patients with IIM-associated ILD; of them, seven had antisynthetase syndrome-associated ILD, one had anti-MDA5 antibody-positive dermatomyositis (DM)-associated ILD, and 2 had DM-associated ILD. Four patients with severe ILD were treated with a combination of rituximab (RTX) (375\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/week for 4\u00a0weeks) and telitacicept (160\u00a0mg\/week). Six patients had refractory IIM-associated ILD; of them, two received RTX (375\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/week for 4\u00a0weeks) in combination with telitacicept (160\u00a0mg\/week), and four were treated with telitacicept (160\u00a0mg\/week) alone because they had an increased infection risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Over the 24-week follow-up, glucocorticoid dosage was reduced to 5\u201310\u00a0mg\/day and that of telitacicept treatment was increased to 160\u00a0mg every 2\u00a0weeks in all patients. These patients exhibited alleviation of rash, joint swelling and pain, muscle pain and weakness, and dyspnea. Compared with before treatment, the Manual Muscle Testing 8 score and PaO2\/FiO2 ratio increased by 25.1% and 28.2% after treatment, respectively. Lung function also exhibited considerable improvements, with percentages of forced vital capacity and diffusing capacity of the lungs for carbon monoxide increasing by 20.4% and 30.2%, respectively. Posttreatment chest high-resolution computed tomography revealed significant improvements compared with baseline. Only one patient experienced a mild lung infection, and no further infections occurred after telitacicept dose was reduced. One patient was administered additional nintedanib for pulmonary fibrosis due to insufficient improvement in lung function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Telitacicept demonstrates substantial clinical efficacy in the treatment of IIM-associated ILD, accompanied by a low infection rate and a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1647543","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:28:56Z","timestamp":1763116136000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Telitacicept for interstitial lung disease associated with idiopathic inflammatory myopathies: an observational study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xue","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MingFang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XinTong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HuanZi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"103056","DOI":"10.1016\/j.autrev.2022.103056","article-title":"Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease","volume":"21","author":"Akiyama","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0133702","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with Anti- synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"978429","DOI":"10.3389\/fimmu.2022.978429","article-title":"The efficacy and safety of tacrolimus on top of glucocorticoids in the management of IIM-ILD: a retrospective and prospective study","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e001296","DOI":"10.1136\/lupus-2024-001296","article-title":"Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study","volume":"12","author":"Chen","year":"","journal-title":"Lupus Sci. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/rheumatology\/kead674","article-title":"The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis","volume":"64","author":"Chen","year":"","journal-title":"Rheumatol. Oxf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J. Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/medicina57040347","article-title":"Management of myositis-associated interstitial lung disease","volume":"57","author":"Fujisawa","year":"2021","journal-title":"Med. Kaunas."},{"key":"B12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/art.41075","article-title":"Proinflammatory histidyl-transfer RNA synthetase-specific CD4+ T cells in the blood and lungs of patients with idiopathic inflammatory myopathies","volume":"72","author":"Galindo-Feria","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11926-023-01105-w","article-title":"Intravenous immunoglobulin in idiopathic inflammatory myopathies: a practical guide for clinical use","volume":"25","author":"Gandiga","year":"2023","journal-title":"Curr. Rheumatol. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12890-015-0105-0","article-title":"Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease","volume":"15","author":"Hamada","year":"2015","journal-title":"BMC Pulm. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e001074","DOI":"10.1136\/lupus-2023-001074","article-title":"Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study","volume":"10","author":"Jin","year":"2023","journal-title":"Lupus Sci. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"937561","DOI":"10.3389\/fmed.2022.937561","article-title":"Treating autoimmune-related interstitial lung disease with B cell depletion","volume":"9","author":"Liossis","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 european league against rheumatism\/american college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/1346-8138.15117","article-title":"Elevated serum B-cell activating factor levels in patients with dermatomyositis: association with interstitial lung disease","volume":"46","author":"Matsushita","year":"2019","journal-title":"J. Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11926-018-0731-7","article-title":"Management of interstitial lung disease in patients with myositis specific autoantibodies","volume":"20","author":"Mecoli","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE)","volume":"20","author":"Mockel","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4046\/trd.2024.0072","article-title":"Idiopathic inflammatory myopathies-associated interstitial lung disease in adults","volume":"88","author":"Moda","year":"2025","journal-title":"Tuberc. Respir. Dis. Seoul."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5386797","DOI":"10.1155\/2017\/5386797","article-title":"Effective administration of rituximab in Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease and refractory cutaneous involvement: a case report and literature review","volume":"2017","author":"Ogawa","year":"2017","journal-title":"Case Rep. Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/blood.v83.2.435.bloodjournal832435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2174\/157339710791330740","article-title":"Interstitial lung disease in idiopathic inflammatory myopathy","volume":"6","author":"Saketkoo","year":"2010","journal-title":"Curr. Rheumatol. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13023-024-03153-6","article-title":"Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis","volume":"19","author":"Shi","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/WCO.0000000000000740","article-title":"Classification of idiopathic inflammatory myopathies: pathology perspectives","volume":"32","author":"Tanboon","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00296-023-05336-z","article-title":"Management of myositis associated interstitial lung disease","volume":"43","author":"Thong","year":"2023","journal-title":"Rheumatol. Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-Positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/MCP.0000000000001000","article-title":"Myositis-associated interstitial lung disease","volume":"29","author":"Vu","year":"2023","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2024","journal-title":"Rheumatol. Oxf."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1509143","DOI":"10.3389\/fimmu.2025.1509143","article-title":"Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1647543\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:29:02Z","timestamp":1763116142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1647543\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":37,"alternative-id":["10.3389\/fphar.2025.1647543"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1647543","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"article-number":"1647543"}}